Private Equity Round in 2023
Tipalti streamlines and automates the way companies make payments to their suppliers, partners, publishers, and crowds. Tipalti provides a comprehensive cloud-based solution that addresses all phases of the payables workflow, from self-service supplier onboarding and management to tax compliance, invoice processing, global funds disbursement, early payments, and AP reporting and payment reconciliation, while helping to ensure the payer in full tax and regulatory compliance. With Tipalti, companies can eliminate up to 80% of their supplier payment workload, helping them scale their business efficiently with global growth while strengthening financial and compliance controls and improving the partner payment experience. Tipalti was founded in 2010 and is headquartered in San Mateo, California.
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.
Gritstone bio develops immunotherapies for cancer and infectious diseases. They started with tumor-specific neoantigens and their programs to include viral antigens displayed on the surface of the virally infected cells. Their biological immune system recognition of targets on the surface of abnormal cells is common to anti-tumor and anti-viral immunity. With the development and commercialization of immunotherapy drugs including checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer.
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.
Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies. The company's Imetelstat, an investigational first-in-class telomerase inhibitor, harnesses Nobel Prize-winning science in a treatment that may change the underlying course of these diseases. Geron was established in 1990 and is headquartered in Foster City, California.
Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases. The company targets the treatment of both niche and prevalent indications, including diabetes, dyslipidemia, and cardiovascular disease.
Viridian Therapeutics provides treatments for patients with diseases that are underserved by therapies. They develops product candidates to treat patients who suffer from thyroid eye disease, a debilitating orphan disease, and early-stage programs focused on targets and indications.
Esme Learning Solutions delivers transformational online learning experiences. Esme Learning supports individual executives, universities, and corporations to deliver technology and the latest business trends that enable learners to transform their careers, launch new ventures and improve business acumen.
Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.
TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Carwow is the smart way to choose and buy a new car. The company helps to connect car buyers to car dealers to make the process as efficient and cost-effective as possible while enabling consumers to interact with an official dealer throughout the transaction process. The company's dealer partners sell more cars in the showroom alone while reducing cost inefficiencies and improving stock turnover.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.
Corium International is a privately-owned company engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. This self-funded product pipeline spans several therapeutic areas and is in various stages of development. Corium also has several partner-funded products with small, medium and large pharmaceutical companies in various stages of development, ranging from manufacturing to research and development.
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
Private Equity Round in 2021
3GTMS develops software that simplifies complex transportation management for shippers, brokers, and 3PLs. They have created a scalable TMS suite that manages the full transportation lifecycle from the rating, routing (including multi-stop and pool distribution optimization), tendering, tracking, tracing, and settlement in a single system.
Better Therapeutics discovers, develops, and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. They use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases to aid in quality of life, reducing the need for medications, and lowering costs. Their products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Their current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia.
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
HiberCell, Inc. is a clinical-stage biotechnology company founded in 2019 and based in New York, New York. It is focused on developing innovative therapeutics aimed at preventing cancer relapse and metastasis. The company's pipeline targets adaptive stress pathways and immune modulation to address treatment resistance, which is a significant factor in cancer-related deaths. HiberCell employs advanced artificial intelligence and machine learning techniques to analyze multi-omic and phenotypic profiles of tumors, generating insights that link this data to clinical outcomes. By doing so, HiberCell aims to enhance treatment strategies and ultimately help patients achieve longer, cancer-free lives. The company is supported by prominent investors in the biotechnology sector who share its vision of transforming the approach to metastatic cancer treatment.
SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
SingleStore is a provider of a database for operational analytics and cloud-native applications. It provides global enterprises with an intelligent database that works on any cloud on-premises or as a service runs transactions and analytics at the same time and lets clients promote their business through analytics and combine semi-structured data into a consolidated big data platform.
CloudBolt provides solutions to help enterprises manage and govern their hybrid cloud and optimize their automation strategy. With CloudBolt, companies can configure and manage private and public cloud resources—quickly, securely, and cost-effectively—while empowering DevOps and end-users with self-service provisioning environments. Today, CloudBolt is deployed in the world’s largest enterprises, across all industries, including financial services, government, healthcare, manufacturing, retail, technology services, and more.
Udacity develops an online learning platform offering programs in artificial intelligence, machine learning, and robotics sector, as well as data science, autonomous systems, and cloud computing. It offers nanodegree programs such as front-end and senior web developer, full-stack web developer, data analyst, machine learning engineer, iOS and Android developer, programming introduction, tech entrepreneur, iOS app development beginning, Ruby beginning, and 2D mobile game developer courses. Udacity's online courses teach the skills that industry employers need and deliver credentials endorsed by employers. The company aims to democratize education making it affordable and accessible to get the jobs they desire to improve their lives. David Stavens, Mike Sokolsky, and Sebastian Thrun founded it in 2011, with its headquarters in Mountain View in California.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.
G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.
SingleStore is a provider of a database for operational analytics and cloud-native applications. It provides global enterprises with an intelligent database that works on any cloud on-premises or as a service runs transactions and analytics at the same time and lets clients promote their business through analytics and combine semi-structured data into a consolidated big data platform.
ZeroFox provides external cybersecurity solutions to help organizations identify, manage, and mitigate social media-based cyber threats. Its solutions protect organizations from the risks introduced by social networking and digital communication platforms. In an age of constant connectivity and social sharing, users have become the primary target for the adversary. By continuously monitoring social platforms for cyber attacks, information loss, social engineering campaigns, account compromise, and fraud, ZeroFox protects organizations from the next generation of digital threats. Leveraging cutting-edge technology and proven security practices, ZeroFox provides both targeted protection and global insights into the world of social media threats.
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Dashlane is a leading credential manager that removes complexity by pairing comprehensive security with ease of use. We are closely attuned to the needs of our users, balancing simple tools with an uncompromising approach to security–a game changer for anyone, but especially for IT admins working to secure their organization. Our team in Paris, New York, and Lisbon is united by a strong sense of community and passion for improving the digital experience. Over 22,000 businesses and 19M users globally use Dashlane for a faster, simpler, and more secure internet.
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
FuelCell Energy designs and operates stationary fuel cell power plants for various applications, including power generation and hydrogen production. The company focuses on decarbonizing energy strategies and offers solutions for utilities, industries, and municipalities. FuelCell Energy aims to provide ultra-clean energy while supporting net-zero commitments.
TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines for various complex diseases. Headquartered in Melbourne, Australia, the company utilizes its proprietary Mesenchymal Precursor Cell (MPC) technology to address conditions such as cardiovascular disorders, orthopedic spine issues, oncology, hematology, and immune-mediated diseases. Key products in clinical development include MSC-100-IV for steroid refractory acute graft versus host disease, MPC-150-IM for advanced heart failure, and MPC-06-ID for chronic low back pain. Additionally, Mesoblast is advancing MPC-300-IV in Phase II trials for biologic refractory rheumatoid arthritis and diabetic kidney diseases. The company collaborates with partners like Tasly Pharmaceutical Group and JCR Pharmaceuticals to expand its offerings in global markets, including the United States, Australia, Singapore, the United Kingdom, and Switzerland. Founded in 2004, Mesoblast aims to provide innovative therapies where conventional treatments have limited efficacy.
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
https://x.com/contentfulContentful, the content platform for digital-first business, helps 30% of the Fortune 500 and thousands of brands around the world create and manage digital experiences for their customers across any channel. It enables greater speed and scale than traditional CMS solutions. The company unifies content in a single hub, structures it for use in any digital channel, and integrates seamlessly with hundreds of other tools through open APIs. Companies such as Chanel, Bang & Olufsen, Shiseido, Shopify, BP, and many others rely on Contentful’s platform.
Merrimack Pharmaceuticals discovers, designs, and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer. Their systems biology is to apply capabilities to build functional and predictive computational models of biological systems such as cell signaling networks.
Acacia Pharma Ltd., a pharmaceutical company, discovers and develops supportive care drugs. The company focuses on cancer supportive care. Its products include APD405, an injectable formulation of an oral drug for the use of nausea and vomiting; APD209, which is for the use of cancer cachexia; and APD421, an intravenous formulation for the use of prevention and treatment of nausea and vomiting. The company also concentrates its discovery efforts in cancer related fatigue, cancer cachexia, and xerostomia. Acacia Pharma Ltd. was incorporated in 2006 and is based in Cambridge, United Kingdom.
Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.
CloudPay Solutions Limited specializes in Software-as-a-Service (SaaS) payroll solutions, providing a comprehensive platform for managed global payroll services tailored for multinational organizations. Established in 1996 and headquartered in Salisbury, United Kingdom, with additional offices in several countries, CloudPay delivers end-to-end payroll management through a unified platform that ensures compliance and consistency across over 130 countries and in more than twenty-five languages. The company’s innovative approach streamlines payroll processes, reduces operational costs, and enhances visibility for organizations, making it a leader in the industry. CloudPay's expertise has been recognized through various awards, including accolades for its technology and service excellence. The company previously operated under the name Patersons Payroll Solutions Limited until its rebranding in 2012.
RumbleON is an online retailer that allows both consumers and dealers to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience. It specializes in Harley-Davidson, e-commerce, recreational vehicles, acquisition, and motorcycles.
Dashlane is a leading credential manager that removes complexity by pairing comprehensive security with ease of use. We are closely attuned to the needs of our users, balancing simple tools with an uncompromising approach to security–a game changer for anyone, but especially for IT admins working to secure their organization. Our team in Paris, New York, and Lisbon is united by a strong sense of community and passion for improving the digital experience. Over 22,000 businesses and 19M users globally use Dashlane for a faster, simpler, and more secure internet.
Metalysis is a UK technology company, headquartered in South Yorkshire, with a solid-state process to produce valuable metal alloy powders primarily used in advanced manufacturing, aerospace and automotive applications. The process, originally invented at The University of Cambridge, UK, and commercialised by Metalysis, is more environmentally friendly and energy efficient than traditional melting technologies. With commercial partners in industry and academia, Metalysis uses its process to produce titanium alloys and niche, high-performance alloys of major interest in advanced manufacturing industries. The Company’s Generation 4 ("Gen 4") technological expansion takes production to industrial scale.
Gibraltar Business Capital (GBC) provides small- to medium-sized business owners fresh and accessible capital alternatives to a commercial bank loan, which is typically more restrictive. With fast, flexible asset based lending and factoring solutions, we act as a bridge to financial stability, delivering lines of credit and specialized small business funding in a highly reliable and always accommodating environment. Our perspective is that there is no one-size-fits-all solution. We look holistically first at the specific issues, history and people involved in a business and tailor capital solutions to fit, not the other way around. We work directly with business owners and their advisors to secure rapid, creative capital when companies need it most—and need it to grow. Meeting a strong demand in today’s shifting marketplace—when even once bankable customers may be faced with a net operating loss, financing before, during and after bankruptcy, or some other financial predicament—our resourceful, professional lending team delivers clear, quick and independent working capital to get businesses back on track. While our corporate office is located in the north suburbs of Chicago, IL, we have sales representation throughout the entire US. Visit our website at www.gibraltarbusinesscapital.com to find a sales representative in your area or contact our corporate office at 847-272-9618 to learn more about how we can help finance your business today.
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Medsphere Systems Corporation provides open source software for the healthcare industry. It offers OpenVista, a portfolio of products and professional services for hospitals, clinics, and integrated delivery networks. The company's OpenVista includes OpenVista Enterprise, an electronic health record solution that offers patient and health information management system, clinical information system, laboratory, pharmacy, radiology, nutrition and food service, and interface suite modules. In addition, the company offers implementation, training, support, and development services. Medsphere Systems Corporation was founded in 2002 and is headquartered in Carlsbad, California.
Intuity Medical develops blood glucose monitoring systems for diabetes management. Their POGO Automatic Blood Glucose Monitoring System is the world’s first FDA-cleared automatic, one-step blood glucose meter that combines lancing, blood collection, and analysis into a single 10-test cartridge. It provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose. The company was founded in 2002 and is headquartered in Fremont, California.
Private Equity Round in 2018
Gynesonics specializes in designing and developing advanced technologies for improving women’s health. It is committed to providing women with a safe and effective incisionless alternative to the invasive surgical techniques of hysterectomy or myomectomy for their symptomatic uterine fibroids.
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.
Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.
Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.
Verastem Oncology is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
Druva delivers data protection and management for the cloud era. Druva Cloud Platform is built on AWS and offered as-a-Service, delivering globally accessible, infinitely scalable and completely autonomous enterprise data resiliency. Customers drive down costs by up to 50 percent by freeing themselves from the burden of unnecessary hardware, capacity planning, and software management. Druva’s patented cloud architecture transforms backup data into an asset, making it more open and accessible so customers can streamline governance, improve cyber resiliency, and gain critical insights to uncover opportunities and expedite decision making.
Mattersight is a provider of enterprise analytics focused on customer and employee interactions and behaviors. Their Behavioral Analytics service captures and analyzes customer and employee interactions, employee desktop data, and other contextual information to optimally route customers to the best available employee, improve operational performance, and predict future customer and employee outcomes. It helps premier brands have better conversations with their customers through enterprise-grade SaaS solutions for contact centers. Mattersight pairs customers to the agent best-suited to handle the customer’s unique personality style. When customers and agents click, organizations gain improved conversation outcomes and measurable revenue growth. Healthcare, telco, financial, and retail enterprises rely on Mattersight to enhance conversations, boost agent performance, and gain operational efficiencies.
Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear.
Aprecia Pharmaceuticals Company develops and manufactures precision drug delivery systems and products. Its products include CustomRelease that provides various time release profiles; ZipDose, a orally dispersing wafers pairing a high dose ceiling with times, taste-masking options, and IR/ER combinations; and NanoDose that is suited for products requiring submilligram doses. The company also offers ImplantaDose, which is suited for post surgical management of infections and associated pain, and sequential release of biomimetic proteins and peptides. Aprecia Pharmaceuticals Company was incorproated in 2003 and is based in Langhorne, Pennsylvania.
Plug Power is a hydrogen and fuel cell company that provides clean hydrogen and zero-emission fuel cell solutions. Plug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell turnkey solutions. The Company’s innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy, and transportation industries to address climate change and energy security, while meeting sustainability goals. Plug Power created the first commercially viable market for hydrogen fuel cell technology. As a result, the Company has deployed over 40,000 fuel cell systems for e-mobility, more than anyone else in the world, and has become the largest buyer of liquid hydrogen, having built and operated a hydrogen highway across North America. Plug Power delivers a significant value proposition to end-customers, including meaningful environmental benefits, efficiency gains, fast fueling, and lower operational costs. Plug Power’s vertically-integrated GenKey solution ties together all critical elements to power, fuel, and provide service to customers such as Amazon, BMW, The Southern Company, Carrefour, and Walmart. The company was founded in 1997 and based in Latham, New York.
Flowonix Medical, Inc. develops an implantable drug pump to deliver therapeutic drugs into the spine. The company operates as a medical device company that designs, develops, and deploys targeted drug delivery platforms to provide physicians an optimal solution for the treatment of their patients' neurological disorders. Its product portfolio includes Prometra, a drug delivery system that delivers Infumorph, a pain medication to patients suffering from long term pain; Prometra Pump, a precision dosing system; and Catheter, that facilitates placement and delivery of medicine within the intrathecal space. Flowonix Medical, Inc. was formerly known as InSet Technologies Incorporated. The company was incorporated in 2005 and is based in Mount Olive, New Jersey. It has an additional office in Mansfield, Massachusetts.
FuelCell Energy designs and operates stationary fuel cell power plants for various applications, including power generation and hydrogen production. The company focuses on decarbonizing energy strategies and offers solutions for utilities, industries, and municipalities. FuelCell Energy aims to provide ultra-clean energy while supporting net-zero commitments.
ClearObject is an IoT Systems Innovator, helping the world’s best companies connect their bold ideas to the Internet of Things. They bring their years of experience, their team of experts and their coalition of leading partners together to make your IoT solutions a reality. ClearObject leverages the combined power of our own experts and our partners to provide world class IoT services. ClearObject aims to be a leader in the internet of everything. We provide clear pathways to our customer’s IoT objectives and their data. With a philosophy of creating connections, the company focuses on helping clients build intelligence into their products and then gain valuable intelligence about them. Based in the Nickel Plate area of Fisher, Indiana, ClearObject seeks to design customized connected solutions for every client, regardless of scale. Utilizing its certification as a certified IBM Watson IoT partner and Google Cloud Platform partner, it can bring current tools and strategies to every client’s table while also providing unique data analysis and explanations about what the information means. The company’s customer-led approach provides clients access to a variety of expertise, including an entire Product Team-as-a-Service. This means every client can tap into a wide range of disciplines and skills, including engineering, analytics, machine learning, AI, app design and more. ClearObject was founded in 2010, the first company to offer Software-as-a-Service (SaaS) and virtual private cloud delivery of IBM software. Over the years, it has earned a variety of local, state and national honors, including being chosen by Inc magazine as the fastest growing IT services firm in the state of Indiana, and a TechPoint MiraAward for Scale-up Company of the Year, in the $5 million to $20 million category. In 2017, it was rebranded as ClearObject. Part of its new corporate identity went beyond cloud computing to a greater focus on helping clients with Internet of Things solutions. Two years later, Egis Capital Partners and ABS Capital Partners acquired a majority interest in ClearObject, a partnership which presented the company with more efficiency and organization, technology industry knowledge and expertise, as well as improved equity to help it better reach its global goals. It recently added a Digital Products business unit which will improve its ability to collaborate with clients and guide them in their complete digital transformations. For more information visit clearobject.com
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
(NYSE MKT: MSTX) We are a San Diego-based biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions.
Proven by the world's most demanding enterprises, including AAA NCNU, Constant Contact, Falck, Hootsuite, Pitney Bowes, Audi, Adobe, Telekom Denmark, Philips, Roku, and VMware, Aria helps enterprises grow their recurring revenue businesses. Aria helps clients take advantage of each customer-driven event − known as revenue moments − with agile billing, active customer engagement, and the rapid development of new products and services. With Aria's end-to-end active monetization platform, global brands can get to market faster with a wider variety of products and services, while maximizing customer satisfaction, retention, and lifetime value.
CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene.
Modumetal develops and licenses a proprietary technology to produce industrial scale nanolaminated alloys with unprecedented performance characteristics. The company offers nanolaminate coatings that are stronger and lighter than steel, more corrosion-resistant, and more durable than other metals using electricity, rather than heat, to reduce the environmental impact of their manufacture. Modumetal enables infrastructure, automotive, aerospace, energy, and construction industries to achieve superior performance at a cost that is competitive with conventional solutions.
Gynesonics specializes in designing and developing advanced technologies for improving women’s health. It is committed to providing women with a safe and effective incisionless alternative to the invasive surgical techniques of hysterectomy or myomectomy for their symptomatic uterine fibroids.
Proterra designs and manufactures zero-emission, heavy-duty electric vehicles, enabling bus fleet operators to significantly reduce operating costs while delivering clean, quiet transportation to local communities across North America. The company’s configurable Catalyst platform is designed to serve the daily mileage needs of a wide range of transit routes on a single charge. With industry-leading durability and energy efficiency based on rigorous U.S. independent testing, Proterra products are proudly designed, engineered, and manufactured in America, with offices in Silicon Valley, South Carolina, and Los Angeles. Proterra's revolutionary battery-electric transit vehicles help fleet operators abandon fossil fuels, improve environmental quality, and reduce operating costs. Together with their customers, they have prevented more than 55 million pounds of greenhouse gases from escaping into the atmosphere and avoided burning some 2 million gallons of fuel. The company was established in 2004 and is based in Burlingame, California, USA.
Proterra designs and manufactures zero-emission, heavy-duty electric vehicles, enabling bus fleet operators to significantly reduce operating costs while delivering clean, quiet transportation to local communities across North America. The company’s configurable Catalyst platform is designed to serve the daily mileage needs of a wide range of transit routes on a single charge. With industry-leading durability and energy efficiency based on rigorous U.S. independent testing, Proterra products are proudly designed, engineered, and manufactured in America, with offices in Silicon Valley, South Carolina, and Los Angeles. Proterra's revolutionary battery-electric transit vehicles help fleet operators abandon fossil fuels, improve environmental quality, and reduce operating costs. Together with their customers, they have prevented more than 55 million pounds of greenhouse gases from escaping into the atmosphere and avoided burning some 2 million gallons of fuel. The company was established in 2004 and is based in Burlingame, California, USA.
Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.
Machine Zone develops mobile games in various genres that include fantasy/RPG/MMO. It offers its games for Android. iPad, iPhone, and iPod Touch platforms. Gabriel Leydon, Halbert Nakagawa, and Michael Sherrill founded Addmired in 2008 that became Machine Zone in March 2012. Its headquarters is in Sunnyvale in California.
ReachLocal provides online marketing solutions for small and medium-sized enterprises. It offers search engine advertising, search engine optimization, web presence and content marketing, retargeting, display advertising, and in app mobile advertising services. The company’s product ReachEdge is lead conversion software that helps local businesses convert leads into customers and gain a deeper understanding of their online marketing ROI. ReachLocal was founded in 2004 and is headquartered in Woodland Hills, California with offices in four regions: Asia-Pacific, Europe, Latin America, and North America.
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
SparkPost is an email sending and deliverability platform that helps senders reliably reach the inbox with powerful solutions. It provides a cloud API solution that enables applications and websites to send and receive emails. Customers including Pinterest, LinkedIn, Twitter, Groupon, Marketo, Zillow, CareerBuilder, the Financial Times, and Comcast send over 5 trillion messages a year, more than 37 percent of the world’s commercial email. These companies choose SparkPost to provide the deliverability, data insights, reliability, and scalability they need to drive customer engagement for their business.
SparkPost is an email sending and deliverability platform that helps senders reliably reach the inbox with powerful solutions. It provides a cloud API solution that enables applications and websites to send and receive emails. Customers including Pinterest, LinkedIn, Twitter, Groupon, Marketo, Zillow, CareerBuilder, the Financial Times, and Comcast send over 5 trillion messages a year, more than 37 percent of the world’s commercial email. These companies choose SparkPost to provide the deliverability, data insights, reliability, and scalability they need to drive customer engagement for their business.
Message Systems optimises their email programme by providing them with email expertise and real-time data at their fingertips. It is a predictive email intelligence company. For inquiries, their email address and contact form are available on their website.
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.
The AspireAssist™ is a breakthrough weight loss solution for people with obesity. Unlike many other weight loss procedures, it's minimally-invasive and reversible. The AspireAssist is now commercially available in selected regions in Europe and beyond, and is currently in clinical trials across the US.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
SOASTA is a performance analytics platform that enables digital business owners to gain unprecedented and continuous performance insights into their real user experience on mobile and web devices in real-time and at scale. With more than 10 million tests performed and more than 100 billion user experiences measured, SOASTA is the digital performance expert trusted by industry‐leading companies, including Experian, Gilt Groupe, Hallmark, Intuit, Microsoft, and Netflix. It was incorporated in 2006 and is headquartered in Mountain View, California with additional offices in the United States and London.
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
Flowonix Medical, Inc. develops an implantable drug pump to deliver therapeutic drugs into the spine. The company operates as a medical device company that designs, develops, and deploys targeted drug delivery platforms to provide physicians an optimal solution for the treatment of their patients' neurological disorders. Its product portfolio includes Prometra, a drug delivery system that delivers Infumorph, a pain medication to patients suffering from long term pain; Prometra Pump, a precision dosing system; and Catheter, that facilitates placement and delivery of medicine within the intrathecal space. Flowonix Medical, Inc. was formerly known as InSet Technologies Incorporated. The company was incorporated in 2005 and is based in Mount Olive, New Jersey. It has an additional office in Mansfield, Massachusetts.